This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Valens Past Earnings Performance
Past criteria checks 0/6
Key information
-67.9%
Earnings growth rate
-44.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 46.4% |
| Return on equity | -297.0% |
| Net Margin | -274.2% |
| Last Earnings Update | 31 Aug 2022 |
Recent past performance updates
Recent updates
These Analysts Just Made A Huge Downgrade To Their The Valens Company Inc. (TSE:VLNS) EPS Forecasts
Mar 05
Some Analysts Just Cut Their The Valens Company Inc. (TSE:VLNS) Estimates
Feb 09Is Valens (TSE:VLNS) Using Debt Sensibly?
Oct 19When Will The Valens Company Inc. (TSE:VLNS) Breakeven?
Mar 24The Valens Company Inc. (TSE:VLNS) Analysts Just Cut Their EPS Forecasts
Jan 22Is Valens (TSE:VLNS) Using Too Much Debt?
Dec 08Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Valens makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 22 | 86 | -236 | 85 | 0 |
| 31 May 22 | 87 | -221 | 84 | 0 |
| 28 Feb 22 | 81 | -69 | 73 | 0 |
| 30 Nov 21 | 78 | -49 | 59 | 0 |
| 31 Aug 21 | 76 | -44 | 50 | -2 |
| 31 May 21 | 73 | -35 | 42 | -1 |
| 28 Feb 21 | 72 | -29 | 37 | -1 |
| 30 Nov 20 | 84 | -21 | 36 | 0 |
| 31 Aug 20 | 98 | 0 | 33 | 3 |
| 31 May 20 | 97 | 9 | 31 | 3 |
| 29 Feb 20 | 88 | 2 | 28 | 3 |
| 30 Nov 19 | 58 | -7 | 26 | 2 |
| 31 Aug 19 | 27 | -18 | 21 | 2 |
| 31 May 19 | 11 | -27 | 17 | 1 |
| 28 Feb 19 | 2 | -19 | 15 | 1 |
| 30 Nov 18 | 0 | -16 | 12 | 0 |
| 31 Aug 18 | 0 | -9 | 9 | 0 |
| 31 May 18 | 0 | -8 | 8 | 0 |
| 28 Feb 18 | 0 | -7 | 8 | 0 |
| 30 Nov 17 | 0 | -4 | 5 | 0 |
| 31 Aug 17 | 0 | -11 | 4 | 0 |
| 31 May 17 | 0 | -11 | 3 | 0 |
| 28 Feb 17 | 0 | -9 | 2 | 0 |
| 30 Nov 16 | 0 | -8 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -1 | 1 | 0 |
Quality Earnings: VLNS is currently unprofitable.
Growing Profit Margin: VLNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VLNS is unprofitable, and losses have increased over the past 5 years at a rate of 67.9% per year.
Accelerating Growth: Unable to compare VLNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VLNS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.5%).
Return on Equity
High ROE: VLNS has a negative Return on Equity (-297.01%), as it is currently unprofitable.